HD Hyundai is proceeding with recruitment in the field of research and development (R&D) for its core new business, aiming to accelerate its bio business. AMC Science, a drug development company established by HD Korea Shipbuilding & Offshore Engineering at the end of last year, is currently conducting its first public recruitment, and the Future Technology Research Institute of HD Korea Shipbuilding & Offshore Engineering is also recruiting researchers for drug development. The focus is on drug development using artificial intelligence (AI).
According to the business community on the 14th, AMC Science is recruiting new and experienced employees until the 17th for 2025. The recruitment will cover research sectors such as protein and antibody discovery, efficacy evaluation, bioinformatics, and non-clinical development, as well as business development and strategic planning. The plan is to build a research organization and intensify drug development through this first public recruitment.
![](data:image/svg+xml;charset=utf-8,<svg height="460px" width="616px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
AMC Science is a drug research and development company incorporated as a subsidiary of HD Korea Shipbuilding & Offshore Engineering, which was established in November last year. The board of directors consists of executives from HD Hyundai and personnel from Asan Medical Center and Seoul Asan Medical Center. CEO Bujihong of HD Hyundai Future Partners and Park Seung-wook, the head of Asan Medical Center, serve as co-CEOs of AMC Science. Former Hanmi Pharmaceutical Vice Chairman Lee Kwan-soo, who led R&D at Hanmi Pharmaceutical for nearly 40 years, was recruited as an external director.
The Future Technology Research Institute AIC, the R&D control tower of HD Korea Shipbuilding & Offshore Engineering, has also been recruiting for AI-based drug development research positions since the 4th. The research will include designing and developing AI models utilizing clinical data, predicting and analyzing protein structures, and discovering new target markers based on AI. With the increasing importance of utilizing AI in drug candidate discovery and development, recruitment for AI research personnel has begun.
HD Hyundai is investing in research and development for new drugs as part of its efforts to foster future business. Kwon Oh-gap, chairman of HD Hyundai, mentioned drug research and development along with small modular reactors (SMR) and fuel cells as new businesses for future preparation in his New Year's speech this year. Vice Chairman Chung Ki-seon of HD Hyundai is leading strategies for identifying new businesses and creating business synergies.
Recently, HD Hyundai has been working to reorganize its scattered bio and healthcare enterprises around AMC Science. After liquidating AMC Bio, which was established for drug development purposes last month, the merger with HD Hyundai Future Partners, which led group bio investments, is scheduled for the 27th.
AMC Science plans to commercialize fundamental medical research from Seoul Asan Medical Center and develop new drugs. Park Seung-wook, head of Asan Medical Center, along with Park Seung-il, head of Seoul Asan Medical Center, and Cho Yu-sook, director of the Institute of Biomedical Research at Seoul Asan Medical Center, will participate in the AMC Science board. Seoul Asan Medical Center is also developing treatments for rare and intractable diseases through an AI-based open platform. It is reported that AMC Science will commercialize the research resources such as drug candidate substances and treatments developed by Seoul Asan Medical Center through technology transfer.
An official from HD Hyundai said, 'It is still early to specifically mention drug candidate substances.'